Verrica Pharmaceuticals has announced its first-quarter 2026 financial results, showcasing significant growth in product revenue and advancements across its clinical pipeline. The company reported a total revenue of $5 million, with a notable 25.4% increase in U.S. Wycanth product revenue compared to the previous year. This growth is complemented by the ongoing global expansion of WYCANT and the progress of its Phase 3 program for common warts. Additionally, Verrica is actively developing BP315 for basal cell carcinoma, which has demonstrated promising Phase 2 data, positioning the company for potential market breakthroughs in dermatology.
Verrica is strategically focused on expanding market access and enhancing treatment options. The introduction of WycanthRx, a non-dispensing pharmacy, aims to streamline prescription fulfillment and improve patient access, a move already yielding positive early adoption. The company’s commitment to innovation is further evidenced by its advancement in the common warts treatment landscape, with a second Phase 3 trial anticipated to begin by mid-2026. These initiatives, coupled with exploring commercialization partnerships in Europe, underscore Verrica's dedication to establishing new standards of care and broadening its global footprint.
Strong Financial Performance and Wycanth's Market Expansion
Verrica Pharmaceuticals achieved a total revenue of $5 million in the first quarter of 2026, reflecting robust financial health and increasing market penetration for its key products. The U.S. Wycanth product revenue surged by 25.4% compared to the first quarter of 2025, demonstrating strong demand and effective commercial strategies. This growth was further supported by an impressive 51.3% increase in dispensed Wycanth applicator units, reaching 15,302 units. The company's strategic decision to launch WycanthRx, a non-dispensing pharmacy, has begun to streamline the prescription fulfillment process, significantly enhancing patient access and contributing to the positive sales trajectory. These efforts are crucial in positioning Wycanth as a leading treatment for molluscum and setting the stage for broader market acceptance.
Beyond its domestic success, Verrica is actively pursuing global expansion for WYCANT. A significant milestone was achieved with the launch of WYCANTT in Japan by its partner, Tory Pharmaceutical, following regulatory approval for molluscum treatment. This international collaboration not only extends WYCANT's reach but also helps offset Verrica's clinical costs for the common warts program through commercial supply agreements. The company is also making strides towards European market entry, with positive feedback from the European Medicines Agency supporting a marketing authorization application. This strategic move aims to tap into the substantial market opportunity in Europe, where Verrica plans to evaluate potential commercialization partnerships to maximize global access for patients who can benefit from WYCANT.
Advancing Pipeline and Future Growth Prospects
Verrica Pharmaceuticals is aggressively moving forward with its clinical pipeline, particularly with its Phase 3 program for common warts and the development of BP315 for basal cell carcinoma. The common warts program has seen considerable progress, with over 50% enrollment achieved in the first Phase 3 trial (CoV2) and the initiation of patient enrollment in the long-term follow-up study. A second Phase 3 trial (CoV3) is targeted to commence by mid-2026, with sites planned in both the United States and Japan. If successful, Wycanth could become the first FDA-approved therapy for common warts in these regions, addressing a condition that affects over 22 million people in the U.S. alone. This expansion leverages the existing commercial infrastructure for molluscum, anticipating significant overlap in treating clinicians and distribution channels.
The company's asset, BP315, for basal cell carcinoma, is also a focal point for future growth, having garnered increasing attention within the dermatology community. Phase 2 study results for BP315 are highly encouraging, showing a 97% objective response rate and an 86% reduction in overall tumor size, with more than half of treated lesions achieving complete histological resolution. Market research indicates strong potential utilization and acceptance among various stakeholders, including dermatologists and oncologists, and a substantial majority of patients expressed willingness to try BP315 before other existing therapeutic options. Verrica retains full global commercial rights to BP315 for non-metastatic skin cancers and is actively exploring funding opportunities and preparing for the Phase 3 program, reinforcing its commitment to addressing significant unmet medical needs and creating long-term shareholder value.